Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...

A machine learning model using existing clinical data may help clinicians screen for comorbid anxiety and depression in ...

Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...

Combining genetic and symptom-based risk scores to predict MS may accelerate the diagnosis of the disease, according to a new ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...

A post-hoc analysis of phase 3 trials presented at ACTRIMS Forum 2025 suggests that tolebrutinib may be more effective in MS ...

A six-month modified Atkins diet intervention in relapsing multiple sclerosis patients led to significant immunometabolic ...

Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who had a greater number of MRI paramagnetic rim lesions at baseline, data show ...

Q4 2024 Earnings Call Transcript March 3, 2025 TG Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.15, ...

Among individuals with relapsing-remitting MS, intermittent calorie restriction and ketogenic diets reduce metabolomic age.

And thanks everyone, for joining us this morning. I'm really excited, to be able to host this call just following the ACTRIMS conference that, was held last week. These meetings, are really so ...

vidofludimus calcium (IMU-838), in two poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025, taking place from February 27 to March ...